SCHEMBL5388933

SCHEMBL5388933

Cc1cc(Br)ccc1Nc1cc(F)ccc1C(=O)NO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
ALDH1A1 P00352 5/20 0.51
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MAP2K1 Q02750 4/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CLCN2 P51788 1/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
DHODH Q02127 1/20 0.40
MAP2K2 P36507 2/20 0.39
THRB P10828 1/20 0.39
GPR35 Q9HC97 1/20 0.38
POLB P06746 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6228943 0.92 MAPK13 (0.47) MAPTALDH1A1MAP2K1CLCN2MAPK13
SCHEMBL6035661 0.88 CLCN2 (0.54) MAPTALDH1A1NPC1RAB9AMAP2K1
SCHEMBL5390982 0.85 MAP2K1 (0.50) MAP2K1MEN1KMT2ACLCN2MAPK13
SCHEMBL6232920 0.83 MAPK13 (0.45) MAPTALDH1A1NPC1RAB9AMEN1
SCHEMBL6948734 0.83 MAPT (0.43) MAPTALDH1A1NPC1RAB9AMAP2K1
SCHEMBL30294563 0.82 ALDH1A1 (0.52) MAPTALDH1A1NPC1RAB9AMAP2K1
SCHEMBL22852829 0.82 ALDH1A1 (0.52) MAPTALDH1A1NPC1RAB9AMAP2K1
SCHEMBL6944337 0.81 CLCN2 (0.38) MAPTALDH1A1NPC1RAB9AMAP2K1
SCHEMBL5396108 0.76 MAP2K1 (0.41) ALDH1A1NPC1RAB9AMAP2K1MEN1
SCHEMBL5389807 0.76 IDO1 (0.47) MAPTALDH1A1MAP2K1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169816-B2 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-20060052608-A1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors WARNER-LAMBERT COMPANY LLC 2006-03-09 US disclosed
EP-1140291-B1 COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR WARNER LAMBERT CO (US) 2005-11-23 EP disclosed
EP-1140062-B1 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER LAMBERT CO (US) 2005-04-06 EP disclosed
US-20050049429-A1 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors BARRETT STEPHEN DOUGLAS (US) 2005-03-03 US disclosed
US-6821963-B2 PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES INHIBIT CERTAIN DUAL SPECIFICITY KINASE ENZYMES INVOLVED IN PROLIFERATIVE DISEASES SUCH AS CANCER, PSORIASIS AND RESTENOSIS; INHIBIT THE PHOSPHORYLATION OF MAP KINASE BY MEK WARNER-LAMBERT COMPANY 2004-11-23 US disclosed
EP-0993439-B1 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER LAMBERT CO (US) 2004-09-29 EP disclosed
CN-1163475-C 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors ��ʲ 2004-08-25 CN disclosed
US-20030078428-A1 Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK BARRETT STEPHEN DOUGLAS (US) 2003-04-24 US disclosed
CN-1261877-A 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors WARNER LAMBERT CO (US) 2000-08-02 CN disclosed
EP-0993439-A1 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-04-19 EP disclosed
WO-1999001426-A1 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078428-A1 Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK MAP2K2, MAP2K7, MAP2K1 MAPT 4312/4885ALDH1A1 633/4885NPC1 3817/4885
US-20060052608-A1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors BRAF, MAPK1, MAPK4 MAPT 4238/4885ALDH1A1 735/4885NPC1 3399/4885
US-20050049429-A1 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors BRAF, MAPK1, MAPK4 MAPT 4238/4885ALDH1A1 735/4885NPC1 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.